A player in the healthcare industry

LFB is a major industrial healthcare player in France. Its plasma-derived medicinal products are produced in two complementary bioproduction sites, in Les Ulis and Lille. A new plant under construction in Arras will triple LFB’s production capacity and thus accelerate its development globally. Two other sites specialise in the production of recombinant medicinal products, in Alès, France and in Massachusetts, United States. The Group also has its own plasma collection centers in Austria and the Czech Republic (Europlasma) and in the United States (LFB American Plasma).

For industrial sites located in France

Les Ulis plant (Essonne) specialises in the upstream processing of plasma-derived medicinal products, from plasma reception to intermediate product.

The Lille plant (Nord) specialises in the downstream processing of plasma derived medicinal products, from intermediates to aseptic filling. Packaging
for LFB’s liquid products is carried out at Carvin (Pas-de-Calais).

The Alès plant : the Alès site is one of the key units of the global bioproduction activities within the LFB. A recombinant protein developed by LFB, as well as clinical and commercial batches of  monoclonal antibodies and recombinant proteins for customers, are manufactured in this plant.
This site is a CDMO (Contract Development & Manufacturing Organisation), offering bioproduction services to third parties, with a top-ranking expertise in biopharmaceuticals.

Major, sustained industrial investment in France

In Les Ulis, Lille and Alès, 30million euros are invested each year in our industrial facilities.

Investment in the new plant in Arras (France) has been implemented and  will enable LFB to step up its production capacity, supporting its international growth and increasing medicines available to patients.